Aelis Farma discloses share buyback program details Jun 22, 2026 12:00PM
Aelis Farma: Availability of the Description of the Share Buyback Program Jun 22, 2026 12:00PM
Results of Aelis Farma Combined General Meeting of June 3, 2026 Jun 4, 2026 12:00PM
Aelis Farma: Combined General Meeting of June 3, 2026: Availability of Preparatory Documents and Participation and Voting Procedures May 13, 2026 12:00PM
Aelis Farma: Availability of the 2025 Universal Registration Document Apr 24, 2026 12:00PM


Apr 7, 2026 01:01AM Aelis Farma receives €458k French grant for obesity research program
Apr 7, 2026 01:00AM Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases
Mar 30, 2026 12:00PM Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook
Mar 21, 2026 05:05AM AELIS Farma starts recruitment for phase 2B down syndrome trial
Mar 21, 2026 05:05AM Aelis Farma announces the successful start of the recruitment of the Phase 2B clinical trial with AEF0217 for the treatment of behavioral and cognitive impairments of people with Down syndrome (Trisom
Jan 26, 2026 12:00PM Aelis Farma Announces Its 2026 Financial Calendar
Jan 12, 2026 01:30AM Aelis Farma Receives a Positive Opinion From EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome
Dec 2, 2025 01:00AM Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome
Sep 25, 2025 04:15PM Aelis Farma: Availability of the 2025 Half-Year Financial Report
Sep 22, 2025 01:00AM Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook
Jun 24, 2025 12:39PM Aelis Farma: Availability of the Description of the Share Buyback Program
May 27, 2025 12:00PM Results of Aelis Farma Combined General Meeting of May 27, 2025
May 6, 2025 12:00PM Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures
Apr 29, 2025 12:00PM Aelis Farma: Availability of the 2024 Universal Registration Document
Apr 1, 2025 12:26PM Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook
Mar 26, 2025 01:00PM Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117
Feb 17, 2025 12:00PM Aelis Farma Announces Its 2025 Financial Calendar
Nov 18, 2024 12:36PM Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome
Sep 26, 2024 12:00PM Aelis Farma: Availability of the 2024 Half-year Financial Report
Sep 25, 2024 12:00PM Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update
Sep 4, 2024 01:00AM Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)
Jun 24, 2024 12:05PM Aelis Farma: Availability of the Description of the Share Buyback Program
Jun 4, 2024 12:00PM Results of Aelis Farma Combined General Meeting of June 4, 2024
May 14, 2024 12:00PM Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures
Apr 25, 2024 12:00PM Aelis Farma: Availability of the 2023 Universal Registration Document
Apr 18, 2024 12:00PM Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder
Apr 2, 2024 11:45AM Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook
Jan 30, 2024 12:00PM Aelis Farma Announces Its 2024 Financial Calendar
Jan 17, 2024 12:23PM Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer
Jan 9, 2024 12:29PM Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis Addiction
Nov 7, 2023 12:31PM Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder
Sep 26, 2023 12:00PM Aelis Farma: Availability of the 2023 Half-Year Financial Report
Sep 25, 2023 12:00PM Aelis Farma Publishes Half-Year Financial Results for 2023 and Confirms Its Development Objectives
Aug 28, 2023 11:45AM Pier Vincenzo Piazza, CEO of Aelis Farma, Receives the Distinguished Achievement Award from the European Behavioural Pharmacology Society (EBPS)
Jul 20, 2023 11:45AM Aelis Farma Takes Part in the 10th Edition of the Gordon Research Conference on the Role of Cannabinoid Receptors in Central Nervous System Disorders
Jul 5, 2023 01:00AM Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction
Jun 21, 2023 12:00PM Aelis Farma: Availability of the Description of the Share Buyback Program
Jun 12, 2023 01:00AM Preclinical Data Demonstrating the Efficacy of AEF0217 in a Genetic Mouse Model of Autism Spectrum Disorder Has Been Presented at the 2nd European Conference on Phelan-McDermid Syndrome
Jun 8, 2023 11:15AM Nature Medicine Publishes Discovery of New Pharmacological Class by Aelis Farma, Phase 2a Study of First Drug Candidate for Cannabis Use Disorder
May 25, 2023 12:00PM Results of Aelis Farma Combined General Meeting of May 24, 2023
May 2, 2023 12:00PM Aelis Farma: Combined General Meeting of May 24, 2023: Availability of Preparatory Documents and Participation and Voting Procedures
Apr 27, 2023 12:00PM Aelis Farma: Publication of the 2022 Universal Registration Document
Apr 24, 2023 12:33PM Degroof Petercam Initiates the Coverage of Aelis Farma With a “Buy” Recommendation
Apr 3, 2023 11:45AM Aelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook
Mar 21, 2023 12:45PM Aelis Farma Has Participated in Two Symposiums Marking World Down Syndrome Day